A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

NCT01009086 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

615

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Psoriatic

Interventions

DRUG: Placebo
DRUG: Ustekinumab 45 mg
DRUG: Ustekinumab 90 mg

Sponsor

Janssen Research & Development, LLC